GeneMatrix enters the high-risk sexual infection diagnosis market
GeneMatrix has completed clinical trials of multiple diagnostic agents for high-risk sexually transmitted infections (STIs) with the next-generation molecular diagnostics original technology, and applied for approval as an item from the Ministry of Food and Drug Safety.
This year, we completed the development of Neoplex STI-7, a new product that can simultaneously test 7 types of sexually transmitted infections genes including Chlamydia trachomatis, and applied for a product license through its subsidiary HBI. We plan to launch the product.
This product is the first product to apply the original C-Tag technology applied for domestic and overseas patents by GeneMatrix, and can simultaneously test a total of 7 high-risk sexually transmitted infections by a single gene amplification, and is a clinical trial for approval by the Ministry of Food and Drug Safety. Excellent clinical performance and accuracy were confirmed through.
As the company's next-generation molecular diagnostics original technology and multi-molecular diagnostics products have already confirmed demand from overseas markets, we plan to enter the advanced overseas markets through European CE certification as well as domestic commercialization based on this approval.